Editorially independent content, supported with advertising
06.30.20
Safe and effective long-duration therapy in wet AMD treatment could be the solution to increasing patient adherence. Are we on the brink of a major breakthrough? Carl Danzig, MD, reviews the phase 2 STAIRWAY study, which evaluated the safety and efficacy of faricimab (Genentech/Roche) for the treatment of wet AMD, and previews the coming phase 3 trials TENAYA and LUCERNE. This editorially independent podcast is supported with advertising.
11.10.25
Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLERahul Khurana, MD; and Arshad Khanani, MD, MA
Editorially independent content, supported by Genentech.
11.06.25
AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt DiseasePeter Kaiser, MD; and Michel Michaelides, MD
Editorially independent content, supported by Genentech.
10.23.25
Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDRAllen Ho, MD; and Charles Wykoff, MD, PhD
Editorially independent content, supported by Genentech.
09.04.25
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDRDavid Lally, MD; and Ehsan Rahimy, MD
Editorially independent content, supported by Genentech
08.21.25
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human GradersJohn Kitchens, MD; Krishna Mukkamala, MD
Editorially independent content, supported by Genentech
06.12.25
Duke AVS Clips: PVR, DR, Imaging, and MTMJason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed
Editorially independent content
06.09.25
Duke AVS Clips: Pediatrics, Anesthesia Trends, and AILejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD
Editorially independent content
06.05.25
Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDsAvni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD
Editorially independent content
05.29.25
ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation DataMarion Munk, MD, PhD; and Diana Do, MD
Editorially independent content, supported by Genentech
05.22.25
ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the PipelineDavid Miller, MD; and Robert Wang, MD
Editorially independent content, supported by Genentech
Show More